查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1654152

血液学癌症诊断市场规模、份额、趋势分析报告：按产品、测试、最终用途、地区、细分预测，2025-2030 年

Blood Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product, By Test, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

血癌诊断市场的成长与趋势

根据Grand View Research, Inc.的最新报告，全球血液癌症诊断市场规模预计到2030年将达到160.4亿美元，2025-2030年期间的复合年增长率为6.87%。

市场的成长受到白血病、淋巴瘤和骨髓瘤等骨髓恶性肿瘤发生率不断上升的推动。此外，由于老年人口的增加，他们更容易患上包括血癌在内的慢性疾病，预计市场将大幅成长。此外，包括 NGS 和其他分子诊断技术在内的技术进步正在提高诊断的准确性和效率，这可能会在预测期内推动市场发展。

在过去的十年中，血癌诊断方法取得了巨大进展，其目的是为了降低日益上升的疾病发生率和死亡率。众所周知，这些进步将提高早期癌症的检测率，但目前已经取得了相当大的进展。例如，NGS可以分析癌细胞的整个基因组，了解基因突变，从而指南精准诊断和个人化治疗。 2022 年 10 月，Sysmex 集团公司 OGT 宣布推出一系列新产品，以增强其不断扩大的 NGS 产品组合。特别是，SureSeq Myeloid Plus 面板旨在识别与各种骨髓疾病相关的基因突变，增强公司在这一重要研究领域的能力。

分子成像技术，例如 SPECT/CT、PET 和流式细胞技术，利用分子造影剂检测指示疾病不同阶段的分子标记并有助于检测和监测。成像技术的进步提高了准确性和早期检测能力，从而推动了市场的发展。全球参与企业正在采用自动影像检查和系统来增加市场占有率。例如，2023年5月，Sysmex Corporation宣布在日本推出其临床流式细胞技术系统。系统包括XF-1600流式细胞仪、PS-10样本製备系统、抗体试剂及其他相关产品。该系统可实现流式细胞技术检测从样品製备到测量结果报告的全过程自动化，有助于提高检测的效率和标准化。

世界各国政府都意识到白血病和淋巴瘤等骨髓恶性肿瘤发生率的上升带来的巨大医疗负担。为了应对这种情况，许多国家推出了全面的国家癌症控制计划，并优先考虑早期发现和筛检工作。例如，美国癌症研究所最近推出了博·拜登癌症登月倡议，以加速癌症研究，使美国更容易获得和负担得起预防性筛检。

市场的主要企业包括 Illumina、InVivoScribe、Ipsogen（Qiagen）、Asuragen（Bio-Techne）、Danaher Corporation、Abbott、SkylineDx、Adaptive Technologies 和 Bio-Rad Laboratories。这些公司正在推行各种策略倡议，包括产品发布和核准，以服务其全球客户。例如，2023 年 9 月，Adaptive Technologies 开始 Epic 整合 clonoSEQ，这是一种用于血癌 MRD 监测的分子诊断测试。此整合将使医疗保健提供者能够直接在 Epic 的 EHR 系统内订购和审查 clonoSEQ 测试结果，从而简化临床决策并改善患者护理。

血液学癌症诊断市场报告重点

  • 根据产品，检测试剂套件和试剂在 2024 年血液学癌症诊断市场中占据最大的销售份额。这一高份额是由用于检测特定生物标记、基因突变和其他指标的检测套件和试剂推动的，使医疗专业人员能够更有效地诊断和治疗疾病。
  • 根据测试，血液检测领域占据市场主导地位，在 2024 年占据最大份额。这是由于用于检测血癌的技术创新和血液检测套组的可用性不断提高。
  • 根据最终用途，医院和诊所占据市场主导地位，在 2024 年占据血液学癌症诊断市场的最大份额。这是因为法医学和医院医学实验室对疾病诊断、血球计数和血型分析的需求不断增加。此外，医院实验室的发展对于满足患者不断变化的需求至关重要，越来越多的医院希望在其环境中提供更广泛的服务。
  • 北美白血病等慢性病发生率较高，需要定期监测和诊断检测，对先进的诊断工具和技术的需求日益增长。
  • 预计在 2025-2030 年预测期内，亚太地区将以最快的速度成长。这得归功于拥有创新设备製造能力和加速诊断研究能力的製造商的存在。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章血液癌症诊断市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 血癌诊断市场分析工具
    • 产业分析 – 波特五力分析
    • PESTEL 分析

第 4 章血液癌症诊断市场：按产品分類的估计和趋势分析

  • 细分仪表板
  • 血液癌症诊断市场：产品变异分析
  • 2018-2030 年市场规模、预测及趋势分析
  • 装置
  • 检测套件和试剂

第 5 章。

  • 2024 年和 2030 年的测试市场占有率
  • 细分仪表板
  • 透过测试展望全球血癌诊断市场
  • 2018-2030 年市场规模、预测及趋势分析
  • 血液检查
  • 影像检查
  • 切片检查
  • 分子检测

第 6 章血液学癌症诊断市场：按最终用途的估计和趋势分析

  • 2024 年及 2030 年终端用途市场占有率
  • 细分仪表板
  • 全球血液癌症诊断市场前景（依最终用途）
  • 2018-2030 年市场规模、预测及趋势分析
  • 医院和诊所
  • 诊断实验室
  • 研究所

第 7 章血癌诊断市场：按地区分類的估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 市场规模、预测趋势分析，2018-2030
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商概况
    • 主要经销商及通路伙伴名单
    • 2024 年主要企业的市场占有率分析
    • Illumina
    • InVivoScribe
    • Ipsogen（Qiagen）
    • Asuragen（Bio-Techne）
    • Danaher Corporation
    • Abbott
    • Sequenta（Adaptive bIoTechnologies）
    • SkylineDx
    • Bio-Rad Laboratories
    • Alercell
    • Sophia Genetics
Product Code: GVR-4-68040-330-3

Blood Cancer Diagnostics Market Growth & Trends:

The global blood cancer diagnostics market size is expected to reach USD 16.04 billion by 2030, registering a CAGR of 6.87% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing incidence of blood malignancies, such as leukemia, lymphoma, and myeloma. The market is further expected to grow significantly due to the increasing elderly population, which is more susceptible to chronic diseases, including blood cancer. In addition, technological advancements, including NGS and other molecular diagnostic techniques, are improving the accuracy & efficiency of diagnosis, which is likely to drive the market over the forecast period.

Over the past decade, significant advancements have been made in approaches to blood cancer diagnostics, all aimed at reducing the growing incidence of diseases and their mortality. While these advancements have been well-documented to increase early cancer detection, there have been considerable advancements. For instance, NGS has enabled the analysis of the entire genome of cancer cells, providing insights into genetic mutations that guide precise diagnosis and tailored treatments. In October 2022, OGT, a Sysmex group, introduced a range of new offerings to augment its expanding NGS product suite. Notably, the SureSeq Myeloid Plus panel was designed to identify genetic mutations associated with various Myeloid disorders, enhancing the company's capabilities in this critical area of research.

Molecular imaging techniques, such as SPECT/CT, PET, and flow cytometry, utilize molecular imaging agents to detect indicative molecular markers at different disease stages, aiding detection & monitoring. Such advancements in imaging technologies offer improved accuracy and early detection capabilities, driving the market. The global players are introducing automatic imaging tests and systems to boost their market share. For instance, in May 2023, Sysmex Corporation announced the launch of the Clinical Flow Cytometry System in Japan. The system includes Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products. This system enables laboratories to automate the entire process of flow cytometry testing, from sample preparation to the reporting of measurement results, contributing to higher efficiency & testing standardization.

Governments across the world have recognized the immense healthcare burden posed by rising incidences, including hematological malignancies such as leukemia & lymphoma. In response, many countries have launched comprehensive national cancer control programs that prioritize early detection and screening efforts. For instance, the American Association of Cancer Research recently launched the Beau Biden Cancer Moonshot initiative to accelerate cancer research and make preventive screening more accessible & affordable for U.S. citizens.

Some of the key players in the market are Illumina, InVivoScribe, Ipsogen (Qiagen), Asuragen(Bio-Techne), Danaher Corporation, Abbott, SkylineDx, Adaptive Technologies, Bio-Rad Laboratories and others. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in September 2023, Adaptive Technologies launched Epic integration for clonoSEQ, a molecular diagnostic test for MRD monitoring in blood cancers. This integration allows healthcare providers to order and review clonoSEQ test results directly within Epic's EHR system, streamlining clinical decision-making and improving patient care.

Blood Cancer Diagnostics Market Report Highlights:

  • Based on product, the assay kits and reagents accounted for the largest revenue share of the blood cancer diagnostics market in 2024. This high share is attributable to assay kits & reagents being designed to detect specific biomarkers, genetic mutations, and other indicators, enabling healthcare professionals to diagnose & treat the disease more effectively
  • Based on tests, blood tests segment dominated the market and accounted for the largest share in 2024. This can be attributed to increasing innovation and availability of blood test kits for blood cancer detection
  • Based on end use, hospitals and clinics dominated the market with the largest share of blood cancer diagnostics market in 2024. This is attributable to growing demand in forensic labs and hospital medical labs for disease diagnosis, blood cell counts, blood typing. Furthermore, Developments in hospital laboratories are crucial to address the evolving needs of patients, and more hospitals aim to provide a wide range of services in their settings
  • North America dominated the market due to the presence of a large number of major market players, North America has a high prevalence of chronic diseases like leukemia These diseases require regular monitoring and diagnostic testing, fueling the demand for advanced diagnostic tools and technologies
  • Asia Pacific is expected to witness the fastest growth over the forecast period from 2025 to 2030, due to the presence of manufacturers with innovative devices manufacturing capabilities coupled with accelerated diagnostic research capabilities

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Test
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Test outlook
    • 2.2.3. End Use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Blood Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of blood cancer
      • 3.2.1.2. Increasing R&D and clinical trials
      • 3.2.1.3. Advancements in diagnostics technologies
      • 3.2.1.4. Rising government initiatives and regulatory support
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High development cost and accessibility barriers
  • 3.3. Blood Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Blood Cancer Diagnostics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Blood Cancer Diagnostics Market: Product Movement Analysis
  • 4.3. Blood Cancer Diagnostics Market Size & Trend Analysis, by product, 2018 to 2030 (USD Million)
  • 4.4. Instruments
    • 4.4.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Assay Kits and Reagents
    • 4.5.1. Assay Kits and Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Blood Cancer Diagnostics Market: Test Estimates & Trend Analysis

  • 5.1. Test Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Blood Cancer Diagnostics Market by Test Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Blood Tests
    • 5.5.1. Blood Tests Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Imaging Tests
    • 5.6.1. Imaging Tests Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Biopsy
    • 5.7.1. Biopsy Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Molecular Test
    • 5.8.1. Molecular Tests Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Blood Cancer Diagnostics Market: End-use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Blood Cancer Diagnostics Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Hospitals and Clinics
    • 6.5.1. Hospitals and Clinics Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Diagnostic Labs
    • 6.6.1. Diagnostic Labs Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Research Institutes
    • 6.7.1. Research Institutes Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Blood Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/Reimbursement
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/Reimbursement
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/Reimbursement
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/Reimbursement
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/Reimbursement
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/Reimbursement
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/Reimbursement
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/Reimbursement
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/Reimbursement
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/Reimbursement
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/Reimbursement
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/Reimbursement
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/Reimbursement
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/Reimbursement
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/Reimbursement
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/Reimbursement
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/Reimbursement
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/Reimbursement
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/Reimbursement
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/Reimbursement
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/Reimbursement
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/Reimbursement
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Illumina
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Services benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. InVivoScribe
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Services benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Ipsogen (Qiagen)
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Services benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Asuragen(Bio-Techne)
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Services benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Danaher Corporation
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Services benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Abbott
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Services benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Sequenta (Adaptive biotechnologies)
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Services benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. SkylineDx
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Services benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Bio-Rad Laboratories
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Services benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Alercell
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Services benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Sophia Genetics
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Services benchmarking
      • 8.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America blood cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 5 North America blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 6 U.S. blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 7 U.S. blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 8 U.S. blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 10 Canada blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 11 Canada blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Mexico blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 13 Mexico blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 14 Mexico blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Europe blood cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 17 Europe blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 18 Europe blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Germany blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 20 Germany blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 21 Germany blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 22 UK blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 23 UK blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 24 UK blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 25 France blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 26 France blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 27 France blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Italy blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 29 Italy blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 30 Italy blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 31 Spain blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 32 Spain blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 33 Spain blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Denmark blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 35 Denmark blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 36 Denmark blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Sweden blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 38 Sweden blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 39 Sweden blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Norway blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 41 Norway blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 42 Norway blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific blood cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 47 China blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 48 China blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 49 China blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Japan blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 51 Japan blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 52 Japan blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 53 India blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 54 India blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 55 India blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 56 South Korea blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 57 South Korea blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 58 South Korea blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Australia blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 60 Australia blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 61 Australia blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Thailand blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 63 Thailand blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 64 Thailand blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Latin America blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 66 Latin America blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 67 Latin America blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 68 Brazil blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 69 Brazil blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 70 Brazil blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 71 Argentina blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 72 Argentina blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 73 Argentina blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 74 MEA blood cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 76 MEA blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 77 MEA blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 78 South Africa blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 79 South Africa blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 80 South Africa blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 84 UAE blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 85 UAE blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 86 UAE blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 87 Kuwait blood cancer diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 88 Kuwait blood cancer diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table 89 Kuwait blood cancer diagnostics market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Blood cancer diagnostics market: market outlook
  • Fig. 14 Blood cancer diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Blood cancer diagnostics market driver impact
  • Fig. 20 Blood cancer diagnostics market restraint impact
  • Fig. 21 Blood cancer diagnostics market strategic initiatives analysis
  • Fig. 22 Blood cancer diagnostics market: Product movement analysis
  • Fig. 23 Blood cancer diagnostics market: Product outlook and key takeaways
  • Fig. 24 Instruments estimates and forecast, 2018 - 2030
  • Fig. 25 Assay kits and reagents market estimates and forecast, 2018 - 2030
  • Fig. 26 Blood cancer diagnostics Market: Test movement analysis
  • Fig. 27 Blood cancer diagnostics market: Test outlook and key takeaways
  • Fig. 28 Blood tests market estimates and forecasts, 2018 - 2030
  • Fig. 29 Imaging tests market estimates and forecasts,2018 - 2030
  • Fig. 30 Biopsy market estimates and forecasts,2018 - 2030
  • Fig. 31 Molecular tests market estimates and forecasts,2018 - 2030
  • Fig. 32 Blood cancer diagnostics market: End-use movement analysis
  • Fig. 33 Blood cancer diagnostics market: End-use outlook and key takeaways
  • Fig. 34 Hospitals and clinics market estimates and forecasts, 2018 - 2030
  • Fig. 35 Diagnostic labs market estimates and forecasts,2018 - 2030
  • Fig. 36 Research institutes market estimates and forecasts, 2018 - 2030
  • Fig. 37 Global blood cancer diagnostics market: Regional movement analysis
  • Fig. 38 Global blood cancer diagnostics market: Regional outlook and key takeaways
  • Fig. 39 Global blood cancer diagnostics market share and leading players
  • Fig. 40 North America market share and leading players
  • Fig. 41 Europe market share and leading players
  • Fig. 42 Asia Pacific market share and leading players
  • Fig. 43 Latin America market share and leading players
  • Fig. 44 Middle East & Africa market share and leading players
  • Fig. 45 North America, by country
  • Fig. 46 North America
  • Fig. 47 North America market estimates and forecasts, 2018 - 2030
  • Fig. 48 U.S. key country dynamics
  • Fig. 49 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 50 Canada country dynamics
  • Fig. 51 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 52 Mexico country dynamics
  • Fig. 53 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 54 Europe
  • Fig. 55 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 56 UK country dynamics
  • Fig. 57 UK market estimates and forecasts, 2018 - 2030
  • Fig. 58 Germany
  • Fig. 59 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 60 France country dynamics
  • Fig. 61 France market estimates and forecasts, 2018 - 2030
  • Fig. 62 Italy country dynamics
  • Fig. 63 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 64 Spain country dynamics
  • Fig. 65 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 66 Denmark country dynamics
  • Fig. 67 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 68 Sweden country dynamics
  • Fig. 69 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 70 Norway country dynamics
  • Fig. 71 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 72 Asia Pacific
  • Fig. 73 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 74 China country dynamics
  • Fig. 75 China market estimates and forecasts, 2018 - 2030
  • Fig. 76 Japan country dynamics
  • Fig. 77 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 78 India country dynamics
  • Fig. 79 India market estimates and forecasts, 2018 - 2030
  • Fig. 80 Thailand country dynamics
  • Fig. 81 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 82 South Korea country dynamics
  • Fig. 83 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 84 Australia country dynamics
  • Fig. 85 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 86 Latin America
  • Fig. 87 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 88 Brazil country dynamics
  • Fig. 89 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 90 Argentina country dynamics
  • Fig. 91 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 92 Middle East and Africa
  • Fig. 93 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 94 South Africa country dynamics
  • Fig. 95 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 96 Saudi Arabia country dynamics
  • Fig. 97 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 98 UAE country dynamics
  • Fig. 99 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 100 Kuwait country dynamics
  • Fig. 101 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 102 Market share of key market players- Blood cancer diagnostics market, 2024
  • Fig. 103 Company Categorization